Evaxion A/S (EVAX)Healthcare | Biotechnology | Horsholm, Denmark | NasdaqCM
3.01 USD
-0.14
(-4.444%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.98 -0.03 (-0.030%) ⇩ (Aug. 28, 2026, 6:56 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:16 a.m. EDT
The immediate outlook is severely clouded by a relentless four-year price collapse, with the stock trading at a fraction of its historical value despite recent minor technical bounces. While the company boasts a pristine balance sheet with minimal debt and a current ratio exceeding five, the business fundamentals are currently broken, evidenced by significant losses, negative operating cash flow, and a forward P/E that indicates no expected earnings. The lack of any dividend history confirms the capital is being reinvested into R&D rather than returned to shareholders. Although analysts see a massive gap between current prices and their targets, suggesting potential for a dramatic recovery if clinical trials succeed, the current trajectory is one of deep distress. For investors, this is a high-risk speculative play on future biotech breakthroughs rather than a sound investment vehicle. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.055372 |
| MSTL | 0.060510 |
| AutoTheta | 0.063554 |
| AutoARIMA | 0.116727 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 0.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.693 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 74.546 |
| Revenue per Share | 0.942 |
| Market Cap | 25,104,048 |
| Forward P/E | -200.67 |
| Beta | 0.25 |
| Profit Margins | -115.54% |
| Previous Name | Evaxion Biotech A/S |
| Website | https://evaxion.ai |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.13513517 |
| Address1 | Dr. Neergaards Vej |
| Address2 | 5th Floor |
| All Time High | 1,252.0 |
| All Time Low | 1.2 |
| Ask | 3.9 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,106,300 |
| Average Daily Volume3 Month | 196,546 |
| Average Volume | 196,546 |
| Average Volume10Days | 1,106,300 |
| Beta | 0.254 |
| Bid | 2.98 |
| Bid Size | 10 |
| Book Value | 1.278 |
| City | Horsholm |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Denmark |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.01 |
| Current Ratio | 5.062 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.16 |
| Day Low | 3.01 |
| Debt To Equity | 74.546 |
| Earnings Call Timestamp End | 1,748,349,000 |
| Earnings Call Timestamp Start | 1,748,349,000 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -8,326,000 |
| Ebitda Margins | -1.11147 |
| Enterprise To Ebitda | -2.187 |
| Enterprise To Revenue | 2.431 |
| Enterprise Value | 18,209,048 |
| Eps Current Year | -0.04 |
| Eps Forward | -0.015 |
| Eps Trailing Twelve Months | -0.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.12402 |
| Fifty Day Average Change | -0.11402011 |
| Fifty Day Average Change Percent | -0.03649788 |
| Fifty Two Week Change Percent | 13.513517 |
| Fifty Two Week High | 12.15 |
| Fifty Two Week High Change | -9.139999 |
| Fifty Two Week High Change Percent | -0.75226337 |
| Fifty Two Week Low | 2.52 |
| Fifty Two Week Low Change | 0.49 |
| Fifty Two Week Low Change Percent | 0.19444445 |
| Fifty Two Week Range | 2.52 - 12.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 5,679,353 |
| Forward Eps | -0.015 |
| Forward P E | -200.66667 |
| Free Cashflow | -5,487,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 46 |
| Fullday Change | -0.14 |
| Fullday Change Percent | -4.44445 |
| Fullday Price | 2.98 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 7,491,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17469 |
| Held Percent Institutions | 0.100530006 |
| Implied Shares Outstanding | 8,340,215 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,736,812,800 |
| Last Split Factor | 1:5 |
| Long Business Summary | Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. |
| Long Name | Evaxion A/S |
| Market | us_market |
| Market Cap | 25,104,048 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_319014926 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -8,655,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 26,271,677 |
| Number Of Analyst Opinions | 4 |
| Open | 3.15 |
| Operating Cashflow | -7,164,000 |
| Operating Margins | -1.16019 |
| Payout Ratio | 0.0 |
| Phone | 45 53 53 18 50 |
| Post Market Change | -0.029999971 |
| Post Market Change Percent | -0.9966768 |
| Post Market Price | 2.98 |
| Post Market Time | 1,787,957,766 |
| Prev Name | Evaxion Biotech A/S |
| Previous Close | 3.15 |
| Price Eps Current Year | -75.25 |
| Price Hint | 4 |
| Price To Book | 2.3552425 |
| Price To Sales Trailing12 Months | 3.3512278 |
| Profit Margins | -1.15539 |
| Quick Ratio | 4.736 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -4.44445 |
| Regular Market Day High | 3.16 |
| Regular Market Day Low | 3.01 |
| Regular Market Day Range | 3.01 - 3.16 |
| Regular Market Open | 3.15 |
| Regular Market Previous Close | 3.15 |
| Regular Market Price | 3.01 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 122,550 |
| Return On Assets | -0.25972 |
| Return On Equity | -1.09856 |
| Revenue Per Share | 0.942 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,340,215 |
| Shares Percent Shares Out | 0.0025 |
| Shares Short | 20,724 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 20,889 |
| Short Name | Evaxion A/S |
| Short Percent Of Float | 0.003 |
| Short Ratio | 1.46 |
| Source Interval | 15 |
| Symbol | EVAX |
| Target High Price | 16.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 11.25 |
| Target Median Price | 10.0 |
| Total Cash | 14,000,000 |
| Total Cash Per Share | 1.679 |
| Total Debt | 7,105,000 |
| Total Revenue | 7,491,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.00758 |
| Two Hundred Day Average Change | -0.9975798 |
| Two Hundred Day Average Change Percent | -0.24892326 |
| Type Disp | Equity |
| Volume | 122,550 |
| Website | https://evaxion.ai |
| Zip | 2,970 |